NCT00434356View on ClinicalTrials.gov

A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

PHASE2TerminatedINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2008

Conditions

Metastatic Breast Cancer

Interventions

DRUG

bevacizumab

Intravenous repeating dose

DRUG

sunitinib

Oral repeating dose

DRUG

paclitaxel

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT00434356 - A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | Biotech Hunter | Biotech Hunter